Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Vyne Therapeutics Inc (VYNE)

Vyne Therapeutics Inc (VYNE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
VYNE Gains on Preclinical Data for IPF Candidate Zacks - Thu Apr 20, 2023

VYNE gains on positive preclinical data evaluating VYN201 for treating idiopathic pulmonary fibrosis.

CRSP : 55.65 (-1.35%)
KALA : 6.40 (-2.53%)
ALLO : 3.04 (-9.79%)
VYNE : 2.57 (+10.78%)
VYNE Therapeutics (NASDAQ: VYNE) Shares Positive Preclinical Data for VYN201 as a Potential Treatment for Idiopathic Pulmonary Fibrosis Spotlight Growth - Wed Apr 19, 2023

VYNE Therapeutics, Inc. (NASDAQ: VYNE) is engaged as a clinical-stage biopharma company, which is focused on the research and development

VYNE : 2.57 (+10.78%)
Wall Street - NYSE Full View
Pre-Market Brief: Stocks Mostly Lower As Hawkish Fed Remarks Weigh On Sentiment, Powell Speech In Focus Barchart - Tue Jan 10, 2023

March S&P 500 futures (ESH23) are trending down -0.08% this morning after three major U.S. benchmark indices ended the regular session mixed following hawkish remarks from two U.S. Federal Reserve officials,...

ESH23 : 3,957.05s (-0.09%)
AAPL : 169.02 (+1.27%)
GOOGL : 159.13 (+0.55%)
MSFT : 409.06 (+0.37%)
NVDA : 796.77 (-3.33%)
OSH : 39.00 (+0.08%)
VYNE : 2.57 (+10.78%)
FRO : 22.72 (-2.95%)
BLI : 1.2000 (-5.88%)
WWW : 10.62 (+1.92%)
VYNE Therapeutics Inc. (VYNE) Reports Q3 Loss, Tops Revenue Estimates Zacks - Thu Nov 10, 2022

VYNE Therapeutics Inc. (VYNE) delivered earnings and revenue surprises of 0% and 67%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

VYNE : 2.57 (+10.78%)
MDWD : 17.59 (+7.19%)
VYNE Therapeutics Announces Results from its Phase 2a Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis Globe Newswire - Wed Aug 10, 2022

BRIDGEWATER, N.J., Aug. 10, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company...

VYNE : 2.57 (+10.78%)
Catalyst Pharmaceutical (CPRX) Q2 Earnings and Revenues Top Estimates Zacks - Tue Aug 9, 2022

Catalyst (CPRX) delivered earnings and revenue surprises of 17.65% and 7.75%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

CPRX : 15.12 (+2.65%)
VYNE : 2.57 (+10.78%)
VYNE Therapeutics to Present at the B&T Cell-Mediated Autoimmune Disease Drug Development Conference Globe Newswire - Tue Jul 19, 2022

BRIDGEWATER, N.J., July 19, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company...

VYNE : 2.57 (+10.78%)
VYNE Therapeutics Completes Enrollment in Phase 2a Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis Globe Newswire - Fri Jun 17, 2022

Top-line Efficacy Results Expected in Approximately 6 to 8 Weeks...

VYNE : 2.57 (+10.78%)
VYNE Therapeutics to Present at HC Wainwright & Co. Global Investment Conference Globe Newswire - Wed May 18, 2022

BRIDGEWATER, N.J., May 18, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company...

VYNE : 2.57 (+10.78%)
VYNE Therapeutics Inc. (VYNE) Reports Q1 Loss, Misses Revenue Estimates Zacks - Thu May 12, 2022

VYNE Therapeutics Inc. (VYNE) delivered earnings and revenue surprises of 6.67% and 67.64%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

VYNE : 2.57 (+10.78%)
HQY : 79.20 (-0.84%)

Barchart Exclusives

3 Dividend Aristocrats to Buy on Every Dip Barchart - 1 hour ago
As markets get wobbly, here are three Dividend Aristocrats to add a little stability to any portfolio. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot